NASDAQ:PRTG

Portage Biotech (PRTG) Stock Forecast, Price & News

$3.84

+0.08 (+2.13%)

(As of 06/8/2023 ET)

Compare

Today's Range: $3.74
▼
$3.97
50-Day Range: $2.73
▼
$3.77
52-Week Range: $2.34
▼
$11.99

Volume: 23,489 shs
Average Volume: 30,609 shs
Market Capitalization: $64.96 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.00

Portage Biotech MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 395.4% Upside
$19.00 Price Target
Short Interest: Healthy
0.41% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.57
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.94) to ($1.12) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

255th out of 986 stocks

Crude Petroleum & Natural Gas Industry

56th out of 78 stocks

3.5

Analyst's Opinion

Consensus Rating
Portage Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.00, Portage Biotech has a forecasted upside of 395.4% from its current price of $3.84.
Amount of Analyst Coverage
Portage Biotech has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.41% of the float of Portage Biotech has been sold short.
Short Interest Ratio / Days to Cover
Portage Biotech has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Portage Biotech has recently decreased by 10.44%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Portage Biotech does not currently pay a dividend.
Dividend Growth
Portage Biotech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRTG.

2.0

News and Social Media Coverage

News Sentiment
Portage Biotech has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Portage Biotech this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Portage Biotech insiders have not sold or bought any company stock.
Percentage Held by Insiders
42.07% of the stock of Portage Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 0.67% of the stock of Portage Biotech is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Portage Biotech are expected to decrease in the coming year, from ($0.94) to ($1.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Portage Biotech is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Portage Biotech is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Portage Biotech has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Portage Biotech (NASDAQ:PRTG) Stock

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors; TT-4, an adenosine receptor type 2B (A2B) inhibitor to treat solid tumors; TT-53, an A2A/A2B inhibitor to treat solid tumors; TT-3, an A2B inhibitor to treat colorectal and gastrointestinal cancers; and NT230-6 that is in Phase I/II clinical trials for the treatment of tumors. It also provides Nanolipogel (NLG) co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products; and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. The company is based in Tortola, British Virgin Islands.

Receive PRTG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter.

PRTG Stock News Headlines

June 5, 2023 | benzinga.com

Why Portage Biotech Stock Is Up Today

June 5, 2023 | finance.yahoo.com

Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting

June 8, 2023 | Behind the Markets (Ad)

"Unknown laser company making HUGE profit from Russia-Ukraine War"

On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>

June 1, 2023 | finance.yahoo.com

Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

May 11, 2023 | americanbankingnews.com

Portage Biotech Inc. (NASDAQ:PRTG) Short Interest Down 34.8% in April

April 29, 2023 | usnews.com

Portage Central High School

April 26, 2023 | finance.yahoo.com

Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

April 19, 2023 | usnews.com

Portage High School

June 8, 2023 | Altimetry (Ad)

Pentagon Consultant—Here's how Biden Wins Landslide Re-election

—but also hand Joe Biden a landslide re-election win. What would America look like if we slide further towards Socialism? Full story and 4 steps you can take,

April 12, 2023 | nytimes.com

Track Covid-19 in Portage County, Wisconsin

March 12, 2023 | benzinga.com

Portage Biotech Stock (NASDAQ:PRTG), Dividends

March 7, 2023 | finance.yahoo.com

Portage Biotech to Present at Oppenheimer’s 33rd Annual Healthcare Conference

March 1, 2023 | finance.yahoo.com

Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022

February 27, 2023 | finance.yahoo.com

Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer

February 23, 2023 | msn.com

Portage Biotech reports FY results

February 15, 2023 | finance.yahoo.com

Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit

January 21, 2023 | seekingalpha.com

PRTG Portage Biotech Inc.

December 2, 2022 | nasdaq.com

How Much Upside is Left in Portage Biotech Inc. (PRTG)? Wall Street Analysts Think 160%

November 30, 2022 | finance.yahoo.com

Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022

November 10, 2022 | technews.tmcnet.com

Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

November 10, 2022 | finance.yahoo.com

Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

November 8, 2022 | finance.yahoo.com

Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck

September 23, 2022 | benzinga.com

7PRTG : HC Wainwright & Co. Maintains Buy...

September 19, 2022 | nasdaq.com

How Much Upside is Left in Portage Biotech Inc. (PRTG)? Wall Street Analysts Think 268%

September 19, 2022 | nasdaq.com

Bears are Losing Control Over Portage Biotech Inc. (PRTG), Here's Why It's a 'Buy' Now

September 8, 2022 | finance.yahoo.com

Portage Biotech to Present at Upcoming Investor Conferences

August 31, 2022 | seekingalpha.com

Portage Biotech GAAP EPS of -$0.13

See More Headlines

PRTG Price History

30 days | 90 days | 365 days | Advanced Chart

PRTG Company Calendar

Last Earnings: 11/22/2021
Today: 6/08/2023
Next Earnings (Estimated): 8/07/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Crude petroleum & natural gas
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PRTG
CUSIP: N/A
CIK: 1095435
Web: www.portagebiotech.com
Phone: 416-929-1806
Fax: N/A
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $19.00
High Stock Price Forecast: $21.00
Low Stock Price Forecast: $18.00
Forecasted Upside/Downside: +406.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.18)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-16,870,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -10.34%
Return on Assets: -8.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.41
Quick Ratio: 6.41

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $12.40 per share
Price / Book: 0.30

Miscellaneous

Outstanding Shares: 16,940,000
Free Float: 9,816,000
Market Cap: $63.59 million
Optionable: Not Optionable
Beta: 1.30

Key Executives

Dr. Ian B. Walters M.B.A. (Age 54)
M.D., CEO & Chairman of Board
Comp: $848.15k

Mr. Allan J. Lee Shaw CPA (Age 58)
Chief Financial Officer
Comp: $430.95k

Mr. Steven Innaimo
VP of Project Management & Operations

Dr. Robert A. Kramer Ph.D.
Chief Scientific Officer

Mr. Brian Wiley (Age 54)
Chief Bus. Officer
Comp: $252.17k

Mr. Joseph Ciavarella
Chief Accounting Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PRTG Stock - Frequently Asked Questions

Should I buy or sell Portage Biotech stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Portage Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRTG shares.
View PRTG analyst ratings or view top-rated stocks.
What is Portage Biotech's stock price forecast for 2023?: 3 Wall Street research analysts have issued 1 year price targets for Portage Biotech's shares. Their PRTG share price forecasts range from $18.00 to $21.00. On average, they anticipate the company's share price to reach $19.00 in the next year. This suggests a possible upside of 406.1% from the stock's current price.
View analysts price targets for PRTG or view top-rated stocks among Wall Street analysts.
How have PRTG shares performed in 2023?: Portage Biotech's stock was trading at $5.2891 at the start of the year. Since then, PRTG shares have decreased by 29.0% and is now trading at $3.7539.
View the best growth stocks for 2023 here.
When is Portage Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our PRTG earnings forecast.
How were Portage Biotech's earnings last quarter?: Portage Biotech Inc. (NASDAQ:PRTG) released its quarterly earnings results on Monday, November, 22nd. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.03.

What is Portage Biotech's stock symbol?: Portage Biotech trades on the NASDAQ under the ticker symbol "PRTG."
Who are Portage Biotech's major shareholders?: Portage Biotech's stock is owned by a number of institutional and retail investors. Top institutional shareholders include MAI Capital Management (0.46%) and Simplex Trading LLC (0.00%).
How do I buy shares of Portage Biotech?: Shares of PRTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Portage Biotech's stock price today?: One share of PRTG stock can currently be purchased for approximately $3.75.
How much money does Portage Biotech make?: Portage Biotech (NASDAQ:PRTG) has a market capitalization of $63.59 million. The company earns $-16,870,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.
How can I contact Portage Biotech?: Portage Biotech's mailing address is Craigmuir Chambers Road Town, Tortola D8, VG1110. The official website for the company is www.portagebiotech.com. The company can be reached via phone at 416-929-1806.

This page (NASDAQ:PRTG) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial